Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B

P. Marcellin, Q. Xie, S. Woon Paik, R. Flisiak, T. Piratvisuth, J. Petersen, T. Asselah, M. Cornberg, D. Ouzan, GR. Foster, G. Papatheodoridis, D. Messinger, L. Regep, G. Bakalos, U. Alshuth, P. Lampertico, H. Wedemeyer,

. 2020 ; 15 (4) : e0230893. [pub] 20200410

Language English Country United States

Document type Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20025085

BACKGROUND AND AIMS: Sustained off-treatment immune control is achievable in a proportion of patients with chronic hepatitis B treated with peginterferon alfa-2a. We evaluated on-treatment predictors of hepatitis B surface antigen (HBsAg) clearance 3 years after peginterferon alfa-2a treatment and determined the incidence of hepatocellular carcinoma. METHODS: A prospective, international, multicenter, observational study in patients with chronic hepatitis B who have been prescribed peginterferon alfa-2a (40KD) in a real-world setting. The primary endpoint was HBsAg clearance after 3 years' follow-up. RESULTS: The modified intention-to-treat population comprised 844 hepatitis B e antigen (HBeAg)-positive patients (540 [64%] completed 3 years' follow-up), and 872 HBeAg-negative patients (614 [70%] completed 3 years' follow-up). At 3 years' follow-up, HBsAg clearance rates in HBeAg-positive and HBeAg-negative populations, respectively, were 2% (16/844) and 5% (41/872) in the modified intention-to-treat population and 5% [16/328] and 10% [41/394] in those with available data. In HBeAg-positive patients with data, Week 12 HBsAg levels <1500, 1500-20,000, and >20,000 IU/mL were associated with HBsAg clearance rates at 3 years' follow-up of 11%, 1%, and 5%, respectively (Week 24 predictability was similar). In HBeAg-negative patients with available data, a ≥10% decline vs a <10% decline in HBsAg at Week 12 was associated with HBsAg clearance rates of 16% vs 4%. Hepatocellular carcinoma incidence was lower than REACH-B (Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B) model predictions. CONCLUSIONS: Sustained off-treatment immune control is achieved with peginterferon alfa-2a in a real-world setting. HBsAg clearance 3 years after completion of peginterferon alfa-2a can be predicted on the basis of on-treatment HBsAg kinetics.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025085
003      
CZ-PrNML
005      
20201222155041.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0230893 $2 doi
035    __
$a (PubMed)32275726
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Marcellin, Patrick $u Hepatologie, Université Paris Diderot, Clichy, France.
245    10
$a Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B / $c P. Marcellin, Q. Xie, S. Woon Paik, R. Flisiak, T. Piratvisuth, J. Petersen, T. Asselah, M. Cornberg, D. Ouzan, GR. Foster, G. Papatheodoridis, D. Messinger, L. Regep, G. Bakalos, U. Alshuth, P. Lampertico, H. Wedemeyer,
520    9_
$a BACKGROUND AND AIMS: Sustained off-treatment immune control is achievable in a proportion of patients with chronic hepatitis B treated with peginterferon alfa-2a. We evaluated on-treatment predictors of hepatitis B surface antigen (HBsAg) clearance 3 years after peginterferon alfa-2a treatment and determined the incidence of hepatocellular carcinoma. METHODS: A prospective, international, multicenter, observational study in patients with chronic hepatitis B who have been prescribed peginterferon alfa-2a (40KD) in a real-world setting. The primary endpoint was HBsAg clearance after 3 years' follow-up. RESULTS: The modified intention-to-treat population comprised 844 hepatitis B e antigen (HBeAg)-positive patients (540 [64%] completed 3 years' follow-up), and 872 HBeAg-negative patients (614 [70%] completed 3 years' follow-up). At 3 years' follow-up, HBsAg clearance rates in HBeAg-positive and HBeAg-negative populations, respectively, were 2% (16/844) and 5% (41/872) in the modified intention-to-treat population and 5% [16/328] and 10% [41/394] in those with available data. In HBeAg-positive patients with data, Week 12 HBsAg levels <1500, 1500-20,000, and >20,000 IU/mL were associated with HBsAg clearance rates at 3 years' follow-up of 11%, 1%, and 5%, respectively (Week 24 predictability was similar). In HBeAg-negative patients with available data, a ≥10% decline vs a <10% decline in HBsAg at Week 12 was associated with HBsAg clearance rates of 16% vs 4%. Hepatocellular carcinoma incidence was lower than REACH-B (Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B) model predictions. CONCLUSIONS: Sustained off-treatment immune control is achieved with peginterferon alfa-2a in a real-world setting. HBsAg clearance 3 years after completion of peginterferon alfa-2a can be predicted on the basis of on-treatment HBsAg kinetics.
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hepatitida B - antigeny povrchové $x metabolismus $7 D006514
650    _2
$a hepatitida B - antigeny e $x metabolismus $7 D006513
650    _2
$a chronická hepatitida B $x farmakoterapie $x metabolismus $7 D019694
650    _2
$a lidé $7 D006801
650    _2
$a interferon alfa $x škodlivé účinky $x terapeutické užití $7 D016898
650    12
$a internacionalita $7 D038622
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a polyethylenglykoly $x škodlivé účinky $x terapeutické užití $7 D011092
650    _2
$a rekombinantní proteiny $x škodlivé účinky $x terapeutické užití $7 D011994
650    _2
$a bezpečnost $7 D012449
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Xie, Qing $u Infectious Diseases, Ruijin Hospital, Shanghai, China.
700    1_
$a Woon Paik, Seung $u Gastroenterology and Hepatology, Sungkyunkwan University School of Medicine, Seoul, South Korea.
700    1_
$a Flisiak, Robert $u Infectious Disease and Hepatology, Medical University of Białystok, Białystok, Poland.
700    1_
$a Piratvisuth, Teerha $u Gastroenterology and Hepatology, Prince of Songkla University, Songkhla, Thailand.
700    1_
$a Petersen, Jörg $u Liver Unit, Asklepios Klinik St. Georg, Hamburg, Germany.
700    1_
$a Asselah, Tarik $u Hepatologie, Université Paris Diderot, Clichy, France.
700    1_
$a Cornberg, Markus $u Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
700    1_
$a Ouzan, Denis $u Service d'Hepatologie, Institut Arnault Tzanck, Saint-Laurent-du-Var, France.
700    1_
$a Foster, Graham R $u Liver Unit, Queen Mary University of London, London, United Kingdom.
700    1_
$a Papatheodoridis, Georgios $u Gastroenterology, Laiko General Hospital, Athens, Greece.
700    1_
$a Messinger, Diethelm $u PROMETRIS GmbH, Mannheim, Germany.
700    1_
$a Regep, Loredana $u Roche s.r.o., Prague, Czech Republic.
700    1_
$a Bakalos, Georgios $u F. Hoffmann-La Roche Ltd, Basel, Switzerland.
700    1_
$a Alshuth, Ulrich $u Roche Pharma AG, Grenzach-Wyhlen, Germany.
700    1_
$a Lampertico, Pietro $u Gastroenterology and Hepatology, University of Milan, Milan, Italy.
700    1_
$a Wedemeyer, Heiner $u Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 15, č. 4 (2020), s. e0230893
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32275726 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155038 $b ABA008
999    __
$a ok $b bmc $g 1599230 $s 1115771
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 15 $c 4 $d e0230893 $e 20200410 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options